• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: BAY 38-7271     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : umbel-rc:DrugProduct, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatSulfonatesyago:Abstraction100002137yago:Agent114778436yago:Alcohol107884567yago:Beverage107881800yago:CausalAgent100007347yago:Chemical114806838yago:Compound114818238yago:Drug103247620yago:DrugOfAbuse103248958yago:Element114840755yago:Fluid114939900yago:Food100021265yago:Liquid114940386yago:Material114580897yago:Matter100020827yago:Part113809207yago:PhysicalEntity100001930yago:Quintessence114847103yago:Relation100031921drugyago:Salt115010703yago:Substance100019613yago:Substance100020090yago:Sulfonate114616410yago:WikicatAlcoholsyago:WikicatPhenolEthersumbel-rc:DrugProduct New Facet based on Instances of this Class

Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to for clinical development, and was in Phase II trials in 2008 but its development appears to have stopped.